EHMT2 is a histone methyltransferase that catalyzes mono- and dimethylation of histone H3 lysine 9 (H3K9me1/me2), establishing epigenetic marks for transcriptional repression through HP1 protein recruitment 1. Beyond histones, EHMT2 methylates non-histone proteins including p53 and DNMT1, linking histone and DNA methylation pathways 2. EHMT2 also mediates H3K56me1 methylation, regulating DNA replication and histone-PCNA interactions 3. Clinically, EHMT2 dysregulation associates with multiple malignancies. In colorectal cancer, EHMT2 inhibition enhances anti-PD1 immunotherapy efficacy by upregulating galectin-7 and converting immunosuppressive microenvironments to T-cell-inflamed ones 4. EHMT2 contributes to epithelial-mesenchymal transition, cancer stemness, and drug resistance across cancer types 5. In Wilms tumor, EHMT2 functions as a prognostic biomarker linked to Wnt/Ξ²-catenin pathway activation 6. Additionally, EHMT2-mediated H3K9me2 balance at the MLL/KMT2A locus controls leukemic amplifications and rearrangements, particularly therapy-induced events 7. In neuronal development, transient EHMT2 inhibition at the progenitor stage accelerates human cortical neuron maturation by releasing epigenetic developmental barriers 8.
No tissue expression data available for this gene.